BAX Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 4.8% compared to Baxter International's net margin of 14.45%. Baxter International's return on equity of -7.38% beat Boston Scientific's return on equity of 9.57%.

Baxter International has a consensus price target of $38.68, signalling upside risk potential of 23.97%. On the other hand Boston Scientific has an analysts' consensus of $116.12 which suggests that it could grow by 12.42%. Given that Baxter International has higher upside potential than Boston Scientific, analysts believe Baxter International is more attractive than Boston Scientific.

Baxter International has a beta of 0.628, which suggesting that the stock is 37.167% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.

Baxter International has a quarterly dividend of $0.17 per share corresponding to a yield of 2.95%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Baxter International pays -90.91% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Baxter International quarterly revenues are $2.6B, which are smaller than Boston Scientific quarterly revenues of $4.7B. Baxter International's net income of $126M is lower than Boston Scientific's net income of $674M. Notably, Baxter International's price-to-earnings ratio is 167.20x while Boston Scientific's PE ratio is 75.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International is 1.34x versus 8.76x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences has a net margin of 4.8% compared to Baxter International's net margin of 19.72%. Baxter International's return on equity of -7.38% beat Gilead Sciences's return on equity of 32.29%.

Baxter International has a consensus price target of $38.68, signalling upside risk potential of 23.97%. On the other hand Gilead Sciences has an analysts' consensus of $115.04 which suggests that it could grow by 17.19%. Given that Baxter International has higher upside potential than Gilead Sciences, analysts believe Baxter International is more attractive than Gilead Sciences.

Baxter International has a beta of 0.628, which suggesting that the stock is 37.167% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.263, suggesting its less volatile than the S&P 500 by 73.697%.

Baxter International has a quarterly dividend of $0.17 per share corresponding to a yield of 2.95%. Gilead Sciences offers a yield of 3.16% to investors and pays a quarterly dividend of $0.79 per share. Baxter International pays -90.91% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Baxter International quarterly revenues are $2.6B, which are smaller than Gilead Sciences quarterly revenues of $6.7B. Baxter International's net income of $126M is lower than Gilead Sciences's net income of $1.3B. Notably, Baxter International's price-to-earnings ratio is 167.20x while Gilead Sciences's PE ratio is 20.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International is 1.34x versus 4.31x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 4.8% compared to Baxter International's net margin of 50.24%. Baxter International's return on equity of -7.38% beat Johnson & Johnson's return on equity of 30.18%.

Baxter International has a consensus price target of $38.68, signalling upside risk potential of 23.97%. On the other hand Johnson & Johnson has an analysts' consensus of $170.19 which suggests that it could grow by 9.33%. Given that Baxter International has higher upside potential than Johnson & Johnson, analysts believe Baxter International is more attractive than Johnson & Johnson.

Baxter International has a beta of 0.628, which suggesting that the stock is 37.167% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.425, suggesting its less volatile than the S&P 500 by 57.471%.

Baxter International has a quarterly dividend of $0.17 per share corresponding to a yield of 2.95%. Johnson & Johnson offers a yield of 3.19% to investors and pays a quarterly dividend of $1.24 per share. Baxter International pays -90.91% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Baxter International quarterly revenues are $2.6B, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Baxter International's net income of $126M is lower than Johnson & Johnson's net income of $11B. Notably, Baxter International's price-to-earnings ratio is 167.20x while Johnson & Johnson's PE ratio is 17.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International is 1.34x versus 4.23x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 4.8% compared to Baxter International's net margin of -907.48%. Baxter International's return on equity of -7.38% beat Moderna's return on equity of -29.23%.

Baxter International has a consensus price target of $38.68, signalling upside risk potential of 23.97%. On the other hand Moderna has an analysts' consensus of $46.96 which suggests that it could grow by 92.62%. Given that Moderna has higher upside potential than Baxter International, analysts believe Moderna is more attractive than Baxter International.

Baxter International has a beta of 0.628, which suggesting that the stock is 37.167% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

Baxter International has a quarterly dividend of $0.17 per share corresponding to a yield of 2.95%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Baxter International pays -90.91% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Baxter International quarterly revenues are $2.6B, which are larger than Moderna quarterly revenues of $107M. Baxter International's net income of $126M is higher than Moderna's net income of -$971M. Notably, Baxter International's price-to-earnings ratio is 167.20x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International is 1.34x versus 3.02x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.